2022年中国病理学指南与共识的STAR评级解读
采用STAR工具评估2022年医学期刊发表的18篇中国病理学指南与共识(指南1篇、共识17篇),发现指南得分21.83分低于总体指南平均43.4分,共识平均27.87分与总体共识28.3分持平,制订过程在证据检索、评价分级、共识方法及注册等方面欠规范。
要点
- 2022年病理学指南仅1篇,STAR得分21.83分,远低于总体指南平均43.4分。
- 17篇共识平均27.87分,与总体共识水平28.3分基本持平。
- 低分领域为计划书、资助、证据、共识方法及可及性,建议强化循证与规范流程。
核心结论
- 2022年病理学指南及共识制订欠规范,未提供证据检索、评价分级及共识达成方法,缺少计划书与注册。
- 建议病理学领域制订者重视循证医学证据,严格遵循指南制订方法与流程。
研究设计与样本
- 采用科学性、透明性和适用性评级工具(STAR)评估2022年医学期刊发表的中国病理学指南和共识。
- 共纳入18篇,包括指南1篇、共识17篇。
主要发现
- 指南得分为21.83分,低于总体指南平均水平(43.4分)。
- 共识平均得分27.87分,与总体共识水平持平(28.3分)。
- 得分高于总体水平的领域为「利益冲突」和「工作组」。
- 得分低于总体水平的领域为「计划书」「资助」「证据」「共识方法」及「可及性」。
临床怎么用
- 病理科医生参考指南/共识时需注意其证据检索与分级方法可能未报告。
- 指南/共识制订者应重视循证证据并严格遵循制订流程以提升科学性、适用性和透明性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The STAR tool was used to evaluate and analyze the science, transparency, and applicability of Chinese pathology guidelines and consensus published in medical journals in 2022. There were a total of 18 pathology guidelines and consensuses published in 2022, including 1 guideline and 17 consensuses. The results showed that the guideline score was 21.83 points, lower than the overall guideline average (43.4 points). Consensus ratings scored an average of 27.87 points, on par with the overall consensus level (28.3 points). Areas that scored above the overall level were "conflict of interest" and "working groups", while areas that scored below the overall level were "proposals", "funding", "evidence", "consensus approaches" and "accessibility". To sum up, the formulation of pathology guidelines and consensuses in 2022 is not standardized, and the evidence retrieval process, evidence evaluation methods and grading criteria for recommendations on clinical issues are not provided in the formulation process; the process and method for reaching consensus are not provided, the plan is lacking, and registration is not carried out. It is therefore suggested that guidelines/consensus makers in the field of pathology should attach importance to evidence-based medical evidence, strictly follow guideline formulation methods and processes, further improve the scientific, applicable and transparent guidelines/consensuses in the field, and better provide support for clinicians and patients. 采用科学性、透明性和适用性的评级工具(STAR)评估并分析2022年医学期刊中发表的中国病理学指南和共识的科学性、透明性和适用性。2022年评审的病理学指南及共识共计18篇,包括指南1篇,共识17篇。评价结果显示,指南得分为21.83分,低于总体指南平均水平(43.4分);共识平均得分27.87分,与总体共识水平持平(28.3分)。得分高于总体水平的领域是“利益冲突”和“工作组”部分,得分低于总体水平的领域是“计划书”“资助”“证据”“共识方法”及“可及性”部分。综上所述,2022年病理学相关指南及共识制订欠规范,在制定过程中未提供有关临床问题推荐意见的证据检索过程、证据评价方法及分级标准,未提供达成共识的过程及方法,缺少计划书,未进行注册等。建议病理学领域指南/共识制订者重视循证医学证据,严格遵照指南制订方法与流程,进一步提升本领域指南/共识的科学性、适用性和透明性,更好地为临床工作者及患者提供支持。.
引用
- Shi XH, Wang SX, Wang Z, et al. [Scientific, transparent and applicable rankings of Chinese pathological guidelines and consensus published in the medical journals in 2022]. Zhonghua Bing Li Xue Za Zhi. 2024. PMID: 38825895. doi:10.3760/cma.j.cn112151-20231105-00333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。